Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy

References

• HoffmanEPBrownRHJrKunkelLMDystrophin: the protein product of the Duchenne muscular dystrophy locusCell1987519199283319190
   PubMed Web of Science ®Google Scholar
• MonacoAPBertelsonCJLiechti-GallatiSMoserHKunkelLMAn explanation for the phenotypic differences between patients bearing partial deletions of the DMD locusGenomics1988290953384440
   PubMed Web of Science ®Google Scholar
• ShigaNTakeshimaYSakamotoHDisruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophyJ Clin Invest1997100220422109410897
   PubMed Web of Science ®Google Scholar
• Tuffery-GiraudSSaquetCThorelDMutation spectrum leading to an attenuated phenotype in dystrophinopathiesEur J Hum Genet2005131254126016077730
   PubMed Web of Science ®Google Scholar
• FlaniganKMDunnDMvonNANonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD geneHum Mutat20113229930821972111
   PubMed Web of Science ®Google Scholar
• FlaniganKMDunnDLarsenCAMedneLBonnemannCBWeissRBBecker muscular dystrophy due to an inversion of exons 23 and 24 of the DMD geneMuscle Nerve20114482282522006698
   PubMed Web of Science ®Google Scholar
• FalzaranoMSScottonCPassarelliCFerliniADuchenne muscular dystrophy: from diagnosis to therapyMolecules201520181681818426457695
   PubMed Web of Science ®Google Scholar
• DrachmanDBToykaKVMyerEPrednisone in Duchenne muscular dystrophyLancet19742140914124140328
   PubMed Web of Science ®Google Scholar
• MendellJRMoxleyRTGriggsRCRandomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophyN Engl J Med1989320159215972657428
   PubMed Web of Science ®Google Scholar
• EscolarDMHacheLPClemensPRRandomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophyNeurology20117744445221753160
   PubMed Web of Science ®Google Scholar
• ScottJMLiSHarperSQViral vectors for gene transfer of micro-, mini-, or full-length dystrophinNeuromuscul Disord200212Suppl 1S23S2912206791
   PubMed Web of Science ®Google Scholar
• GregorevicPBlankinshipMJAllenJMSystemic delivery of genes to striated muscles using adeno-associated viral vectorsNat Med20041082883415273747
   PubMed Web of Science ®Google Scholar
• KoniecznyPSwiderskiKChamberlainJSGene and cell-mediated therapies for muscular dystrophyMuscle Nerve20134764966323553671
   PubMed Web of Science ®Google Scholar
• YueYGhoshALongCA single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogsMol Ther2008161944195218827804
   PubMed Web of Science ®Google Scholar
• LaiYYueYLiuMEfficient in vivo gene expression by trans-splicing adeno-associated viral vectorsNat Biotechnol2005231435143916244658
   PubMed Web of Science ®Google Scholar
• AcsadiGDicksonGLoveDRHuman dystrophin expression in mdx mice after intramuscular injection of DNA constructsNature19913528158181881437
   PubMed Web of Science ®Google Scholar
• BertoniCJarrahianSWheelerTMEnhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integrationProc Natl Acad Sci U S A200610341942416387861
   PubMed Web of Science ®Google Scholar
• RomeroNBBraunSBenvenisteOPhase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophyHum Gene Ther2004151065107615610607
   PubMed Web of Science ®Google Scholar
• AlterJLouFRabinowitzASystemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNat Med20061217517716444267
   PubMed Web of Science ®Google Scholar
• LuQLMannCJLouFFunctional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouseNat Med200391009101412847521
   PubMed Web of Science ®Google Scholar
• De AngelisFGSthandierOBerarducciBChimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cellsProc Natl Acad Sci U S A2002999456946112077324
   PubMed Web of Science ®Google Scholar
• van DeutekomJCBremmer-BoutMJansonAAAntisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cellsHum Mol Genet2001101547155411468272
   PubMed Web of Science ®Google Scholar
• WiltonSDFallAMHardingPLMcCloreyGColemanCFletcherSAntisense oligonucleotide-induced exon skipping across the human dystrophin gene transcriptMol Ther2007151288129617285139
   PubMed Web of Science ®Google Scholar
• MendellJRCampbellKRodino-KlapacLDystrophin immunity in Duchenne’s muscular dystrophyN Engl J Med20103631429143720925545
   PubMed Web of Science ®Google Scholar
• Rodino-KlapacLRMontgomeryCLBremerWGPersistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular deliveryMol Ther20101810911719904237
   PubMed Web of Science ®Google Scholar
• VoitTTopalogluHStraubVSafety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 studyLancet Neurol20141398799625209738
   PubMed Web of Science ®Google Scholar
• HammondSMWoodMJAPRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophyCurr Opin Mol Ther20101247848620677099
   PubMed Web of Science ®Google Scholar
• CirakSFengLAnthonyKRestoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophyMol Ther20122046246722086232
   PubMed Web of Science ®Google Scholar
• CirakSRechavala-GomezaVGuglieriMExon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyLancet201137859560521784508
   PubMed Web of Science ®Google Scholar
• MendellJRRodino-KlapacLRSahenkZEteplirsen for the treatment of Duchenne muscular dystrophyAnn Neurol20137463764723907995
   PubMed Web of Science ®Google Scholar
• TinsleyJMPotterACPhelpsSRFisherRTrickettJIDaviesKEAmelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgeneNature19963843493538934518
   PubMed Web of Science ®Google Scholar
• TinsleyJDeconinckNFisherRExpression of full-length utrophin prevents muscular dystrophy in mdx miceNat Med19984144114449846586
   PubMed Web of Science ®Google Scholar
• GilbertRNalbanogluJTinsleyJMMassieBDaviesKEKarpatiGEfficient utrophin expression following adenovirus gene transfer in dystrophic muscleBiochem Biophys Res Commun19982422442479439643
   PubMed Web of Science ®Google Scholar
• WakefieldPMTinsleyJMWoodMJGilbertRKarpatiGDaviesKEPrevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigeneGene Ther2000720120410694796
   PubMed Web of Science ®Google Scholar
• KragTOBogdanovichSJensenCJHeregulin ameliorates the dystrophic phenotype in mdx miceProc Natl Acad Sci U S A2004101138561386015365169
   PubMed Web of Science ®Google Scholar
• TinsleyJMFaircloughRJStorerRDaily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mousePLoS One20116e1918921573153
   PubMed Web of Science ®Google Scholar
• TinsleyJRobinsonNWilsonFXHorneGFaircloughRJDaviesKFuture clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)Neuromuscular Disord201323813
   Web of Science ®Google Scholar
• BertoniCTherapy development for neuromuscular diseases: translating hope into promiseFuture Neurol20138399401
   Google Scholar
• BogdanovichSKragTOBartonERFunctional improvement of dystrophic muscle by myostatin blockadeNature200242041842112459784
   PubMed Web of Science ®Google Scholar
• WagnerKRMcPherronACWinikNLeeSJLoss of myostatin attenuates severity of muscular dystrophy in mdx miceAnn Neurol20025283283612447939
   PubMed Web of Science ®Google Scholar
• HaidetAMRizoLHandyCLong-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitorsProc Natl Acad Sci U S A20081054318432218334646
   PubMed Web of Science ®Google Scholar
• CohnRDvanECHabashiJPAngiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic statesNat Med20071320421017237794
   PubMed Web of Science ®Google Scholar
• BishLTYarchoanMSleeperMMChronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic micePLoS One20116e2085621731628
   PubMed Web of Science ®Google Scholar
• SpurneyCFSaliAGuerronADLosartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx miceJ Cardiovasc Pharmacol Ther201116879521304057
   PubMed Web of Science ®Google Scholar
• MessinaSBittoAAguennouzMNuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx miceExp Neurol200619823424116410003
   PubMed Web of Science ®Google Scholar
• GroundsMDTorrisiJAnti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosisFASEB J20041867668215054089
   PubMed Web of Science ®Google Scholar
• PiernoSNicoBBurdiRRole of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approachNeuropathol Appl Neurobiol20073334435917493014
   PubMed Web of Science ®Google Scholar
• HodgettsSRadleyHDaviesMGroundsMDReduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx miceNeuromuscul Disord20061659160216935507
   PubMed Web of Science ®Google Scholar
• PiersATLavinTRadley-CrabbHGBakkerAJGroundsMDPinnigerGJBlockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal miceNeuromuscul Disord20112113214121055937
   PubMed Web of Science ®Google Scholar
• PetersonJMKlineWCananBDPeptide-based inhibition of NF-kappaB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophyMol Med20111750851521267511
   PubMed Web of Science ®Google Scholar
• PeayHLTibbenAFisherTBrennaEBieseckerBBExpectations and experiences of investigators and parents involved in a clinical trial for Duchenne/Becker muscular dystrophyClin Trials201411778524311736
   PubMed Web of Science ®Google Scholar
• PeayHLHollinIFischerRBridgesJFA community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophyClin Ther20143662463724852596
   PubMed Web of Science ®Google Scholar
• FransonTRPeayHBenefit-risk assessments in rare disorders: the case for therapeutic development in Duchenne muscular dystrophy as the prototype for new approaches Available from: http://www.parentprojectmdorg/site/DocServer/br_paper_v11__2_pdf;jsessionid=2C381495CB3753608053FD8DD624B686app247d?docID=14503Accessed April 16, 2016
   Google Scholar
• US Food and Drug Administration (FDA)Enhancing benefit-risk assessment in regulatory decision-making Available from: http://www.fdagov/forindustry/userfees/prescriptiondruguserfee/ucm326192htm2014Accessed March 1, 2014
   Google Scholar
• Human Gene Mutation Database Available from: http://www.hgmd.orgwww.hgmd.orgAccessed March 1, 2016
   Google Scholar
• MortMIvanovDCooperDNChuzhanovaNAA meta-analysis of nonsense mutations causing human genetic diseaseHum Mutat2008291037104718454449
   PubMed Web of Science ®Google Scholar
• LeeHLRDoughertyJPPharmaceutical therapies to recode nonsense mutations in inherited diseasesPharmacol Ther201213622726622820013
   PubMed Web of Science ®Google Scholar
• KeelingKMXueXGunnGBedwellDMTherapeutics based on stop codon readthroughAnnu Rev Genomics Hum Genet20141537139424773318
   PubMed Web of Science ®Google Scholar
• MullardAEMA reconsiders ‘read-through’ drug against Duchenne muscular dystrophy following appealNat Biotech201432706
   PubMed Web of Science ®Google Scholar
• AllenL-ARaetzCRHPartial phenotypic suppression of a peroxisome-deficient animal cell mutant treated with aminoglycoside G418J Biol Chem199226713191131991618823
   PubMed Web of Science ®Google Scholar
• BedwellDMKaenjakABenosDJSuppression of a CFTR premature stop mutation in a bronchial epithelial cell lineNat Med19973128012849359706
   PubMed Web of Science ®Google Scholar
• HowardMFrizzellRABedwellDMAminoglycoside antibiotics restore CFTR function by overcoming premature stop mutationsNat Med199624674698597960
   PubMed Web of Science ®Google Scholar
• Barton-DavisERCordierLShoturmaDILelandSESweeneyHLAminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx miceJ Clin Invest199910437538110449429
   PubMed Web of Science ®Google Scholar
• KeelingKMBrooksDAHopwoodJJLiPThompsonJNBedwellDMGentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulationHum Mol Genet20011029129911159948
   PubMed Web of Science ®Google Scholar
• DuMJonesJRLanierJAminoglycoside suppression of a premature stop mutation in a Cftr−/− mouse carrying a human CFTR-G542X transgeneJ Mol Med20028059560412226741
   PubMed Web of Science ®Google Scholar
• OgleJMRamakrishnanVStructural insights into translational fidelityAnnu Rev Biochem20057412917715952884
   PubMed Web of Science ®Google Scholar
• OgleJMBrodersenDEClemonsWMJrTarryMJCarterAPRamakrishnanVRecognition of cognate transfer RNA by the 30S ribosomal subunitScience200129289790211340196
   PubMed Web of Science ®Google Scholar
• PurohitPSternSInteractions of a small RNA with antibiotic and RNA ligands of the 30S subunitNature19943706596628065453
   PubMed Web of Science ®Google Scholar
• WilhelmJMJessopJJPettittSEAminoglycoside antibiotics and eukaryotic protein synthesis: stimulation of errors in the translation of natural messengers in extracts of cultured human cellsBiochemistry19781711491153656379
   PubMed Web of Science ®Google Scholar
• SunJChenMXuJLuoJRelationships among stop codon usage bias, its context, isochores, and gene expression level in various eukaryotesJ Mol Evol20056143744416170455
   PubMed Web of Science ®Google Scholar
• BonettiBFuLMoonJBedwellDMThe efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiaeJ Mol Biol19952513343457650736
   PubMed Web of Science ®Google Scholar
• TateWPPooleESHorsfieldJATranslational termination efficiency in both bacteria and mammals is regulated by the base following the stop codonBiochem Cell Biol199573109511038722026
   PubMed Web of Science ®Google Scholar
• SicinskiPGengYRyder-CookASBarnardEADarlisonMGBarnardPJThe molecular basis of muscular dystrophy in the mdx mouse: a point mutationScience1989244157815802662404
   PubMed Web of Science ®Google Scholar
• DeLANicoBRollandJFGentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscleNeurobiol Dis20083224325318694830
   PubMed Web of Science ®Google Scholar
• PolitanoLNigroGNigroVGentamicin administration in Duchenne patients with premature stop codon. Preliminary resultsActa Myol200322152112966700
   PubMedGoogle Scholar
• WagnerKRHamedSHadleyDWGentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutationsAnn Neurol20014970671111409421
   PubMed Web of Science ®Google Scholar
• MalikVRodino-KlapacLRViolletLMendellJRAminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophyTher Adv Neurol Disord2010337938921179598
   PubMedGoogle Scholar
• GoldmannTOverlackNMollerFA comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutationEMBO Mol Med201241186119923027640
   PubMed Web of Science ®Google Scholar
• ArakawaMShiozukaMNakayamaYNegamycin restores dystrophin expression in skeletal and cardiac muscles of mdx miceJ Biochem (Tokyo)200313475175814688241
   PubMed Web of Science ®Google Scholar
• HamadaKTaguchiAKotakeMStructure-activity relationship studies of 3-epi-deoxynegamycin derivatives as potent readthrough drug candidatesACS Med Chem Lett2015668969426101575
   PubMed Web of Science ®Google Scholar
• DuLDamoiseauxRNahasSNonaminoglycoside compounds induce readthrough of nonsense mutationsJ Exp Med20092062285229719770270
   PubMed Web of Science ®Google Scholar
• KayaliRKuJMKhitrovGJungMEPrikhodkoOBertoniCRead-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophyHum Mol Genet2012214007402022692682
   PubMed Web of Science ®Google Scholar
• JungMEKuJMDuLHuHGattiRASynthesis and evaluation of compounds that induce readthrough of premature termination codonsBioorg Med Chem Lett2011215842584821873052
   PubMed Web of Science ®Google Scholar
• WelchEMBartonERZhuoJPTC124 targets genetic disorders caused by nonsense mutationsNature2007447879117450125
   PubMed Web of Science ®Google Scholar
• AuldDSThorneNMaguireWFIngleseJMechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppressionProc Natl Acad Sci U S A20091063585359019208811
   PubMed Web of Science ®Google Scholar
• AuldDSLovellSThorneNMolecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124Proc Natl Acad Sci U S A20101074878488320194791
   PubMed Web of Science ®Google Scholar
• McElroySPNomuraTTorrieLSA lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assaysPLoS Biol201311e100159323824517
   PubMed Web of Science ®Google Scholar
• DranchakPKDiPESnowdenANonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutationsJ Cell Biochem20111121250125821465523
   PubMed Web of Science ®Google Scholar
• KoopmannTTVerkerkAOBezzinaCRde BakkerJMWildeAAThe chemical compound PTC124 does not affect cellular electrophysiology of cardiac ventricular myocytesCardiovasc Drugs Ther201226414522065308
   PubMed Web of Science ®Google Scholar
• BrummHMuhlhausJBolzeFRescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-throughObesity (Silver Spring)2012201074108121738238
   PubMed Web of Science ®Google Scholar
• DuMLiuXWelchEMHirawatSPeltzSWBedwellDMPTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse modelProc Natl Acad Sci U S A20081052064206918272502
   PubMed Web of Science ®Google Scholar
• SarkarCZhangZMukherjeeABStop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patientsMol Genet Metab201110433834521704547
   PubMed Web of Science ®Google Scholar
• TanLNarayanSBChenJMeyersGDBennettMJPTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutationJ Inherit Metab Dis20113444344721253826
   PubMed Web of Science ®Google Scholar
• GoldmannTOverlackNWolfrumUNagel-WolfrumKPTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1CHum Gene Ther20112253754721235327
   PubMed Web of Science ®Google Scholar
• YuHLiuXHuangJZhangYHuRPuJComparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndromeInt J Mol Med20143372973524366185
   PubMed Web of Science ®Google Scholar
• FangYWYangSSChauTTherapeutic effect of prenatal alkalization and PTC124 in Na(+)/HCO3(−) cotransporter 1 p.W516* knock-in miceGene Ther20152237438125716530
   PubMed Web of Science ®Google Scholar
• HirawatSWelchEMElfringGLSafety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteersJ Clin Pharmacol20074743044417389552
   PubMed Web of Science ®Google Scholar
• KeremEHirawatSArmoniSEffectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trialLancet200837271972718722008
   PubMed Web of Science ®Google Scholar
• BonnemannCFinkelRWongCG.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD) [abstract]Neuromuscul Disord200717783
   Web of Science ®Google Scholar
• BushbyKFinkelRWongBAtaluren treatment of patients with nonsense mutation dystrophinopathyMuscle Nerve20145047748725042182
   PubMed Web of Science ®Google Scholar
• ATS statement: guidelines for the six-minute walk testAm J Respir Crit Care Med200216611111712091180
   PubMed Web of Science ®Google Scholar
• ButlandRJPangJGrossERWoodcockAAGeddesDMTwo-, six-, and 12-minute walking tests in respiratory diseaseBr Med J (Clin Res Ed)198228416071608
   PubMed Web of Science ®Google Scholar
• McDonaldCMHenricsonEKHanJJThe 6-minute walk test as a new outcome measure in Duchenne muscular dystrophyMuscle Nerve20104150051019941337
   PubMed Web of Science ®Google Scholar
• LynnSAartsma-RusABushbyKMeasuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophyNeuromuscul Disord2015259610525307856
   PubMed Web of Science ®Google Scholar
• McDonaldCMHenricsonEKAbreschRTThe 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter studyMuscle Nerve20134834335623681930
   PubMed Web of Science ®Google Scholar
• McDonaldCMHenricsonEKAbreschRTThe 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter studyMuscle Nerve20134835736823674289
   PubMed Web of Science ®Google Scholar
• HenricsonEAbreschRHanJJThe 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one yearPLoS Curr20135
   PubMedGoogle Scholar
• OwenSCDoakAKGaneshANColloidal drug formulations can explain “bell-shaped” concentration-response curvesACS Chem Biol2014977778424397822
   PubMed Web of Science ®Google Scholar
• AnwerKEarleKAShiMSynergistic effect of formulated plasmid and needle-free injection for genetic vaccinesPharm Res19991688989510397610
   PubMed Web of Science ®Google Scholar
• LiMAndersson-LendahlMSejersenTArnerAMuscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatmentFASEB J2014281593159924371125
   PubMed Web of Science ®Google Scholar
• PTC Therapeutics press release Available from: http://ir.ptcbio.com/releasedetail.cfm?releaseid=936905Accessed March 1, 2016
   Google Scholar
• OuyangLGrosseSDKennesonAHealth care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured populationJ Child Neurol20082388388818403582
   PubMed Web of Science ®Google Scholar
• LarkindaleJYangWHoganPFCost of illness for neuromuscular diseases in the United StatesMuscle Nerve20144943143823836444
   PubMed Web of Science ®Google Scholar
• LandfeldtELindgrenPBellCFThe burden of Duchenne muscular dystrophy: an international, cross-sectional studyNeurology20148352953624991029
   PubMed Web of Science ®Google Scholar
• FlaniganKMCecoELamarKMLTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophyAnn Neurol20137348148823440719
   PubMed Web of Science ®Google Scholar
• BelloLKesariAGordish-DressmanHGenetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History StudyAnn Neurol20157768469625641372
   PubMed Web of Science ®Google Scholar